While ABCB1 expression is generally elevated in CML, its predictive value for relapse following TKI discontinuation is limited, as evidenced by the observed downregulation of ABCB1 in relapsed patients upon TKI withdrawal [75,76]. Here, ABCB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.